At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 190 enrolled
Drug / intervention
reslizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002
In Brief
A Phase 3 clinical trial evaluating reslizumab for Eosinophilic Esophagitis. Completed, enrolled 190 participants across 36 sites in 2 countries.
Detailed Summary
This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434). The goal of the study is to show longer term safety and efficacy in pediatric subjects who have eosinophilic esophagitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis
CountriesCanada, United States
CollaboratorsCephalon
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartJul 2008
Primary CompletionJan 2012
TodayJul 2026
First PostedMar 13, 2008
Enrollment StartJul 1, 2008
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.3 years ago
Interventions
reslizumabdrug